January 1, 2012

Neurimmune acquires USD 1.9m funding from Swiss CTI

Neurimmune acquires USD 1.9m funding from Swiss CTI for its innovative program in type-2 diabetes an d for starting a new project by applying its proprietary RTM technology in infectious disease. Both publicly funded collaborative projects are accompanied by collaboration agreements ensuring Neurimmune’s full and exclusive access to related IP rights.